Peoples Hospital of Zhongshan
Peoples Hospital of Zhongshan
Ding M.-X.,Peoples Hospital of Zhongshan |
Lin S.-H.,Peoples Hospital of Zhongshan |
Li L.-M.,Peoples Hospital of Zhongshan |
Hou B.,Sun Yat Sen University |
And 4 more authors.
Chinese Journal of Tissue Engineering Research | Year: 2013
BACKGROUND: Use of scaffolds loaded with bone marrow mesenchymal stem cells for treatment of central nervous system injury is still in the stage of laboratory study. OBJECTIVE: To evaluate the biocompatibility of acellular brain tissue scaffold with rat bone marrow mesenchymal stem cells in vitro and to testify whether the material could be used as a carrier for central nervous system tissue engineering. METHODS: Bone marrow mesenchymal stem cells were isolated and purified by whole bone marrow method, and the acellular brain tissue scaffold was made by both physical and chemical extraction methods. Bone marrow mesenchymal stem cells transfected by green fluorescent protein were cultured and compounded onto acellular brain tissue scaffold in vitro. The microstructure of the materials and the morphological changes of bone marrow mesenchymal stem cells compounded onto the acellular brain tissue scaffold were observed under inverted phase microscope, scanning electron microscope, and confocal laser scanning microscope. RESULTS AND CONCLUSION: The acellular brain tissue scaffold had the structure of three-dimensional network. The cells grew in an adherent way on the acellular brain tissue scaffold and had normal shape in vitro. The rat acellular brain tissue scaffold has good biocompatibility with bone marrow mesenchymal stem cells and might be used as a biological material for central nervous system tissue engineering.
Chen J.-G.,Sun Yat Sen University |
Chen J.-G.,Taizhou Municipal Hospital |
Lai W.,Sun Yat Sen University |
Jiang Y.,Peoples Hospital of Zhongshan
Acta Academiae Medicinae Sinicae | Year: 2012
Objective: To investigate the change of Th17/Treg cell in patients with psoriasis arthritis (PA) and its clinical significance. Methods: The levels of IL-17 and TGF-β1 were measured by enzyme-linked immunosorbent assay (ELISA) in PA patients (n = 35) and healthy controls (n = 30). The frequencies of Th17 and Treg in the peripheral blood were detected by flow cytometry. Results: Compared with the healthy controls, Th17/Treg in peripheral blood were significantly increased (P < 0.05), Th17-related cytokine IL-17 significantly increased (P < 0. 05), and TGF-β1 significantly decreased (P < 0.05) in the PA patients. Conclusion: Th17/Treg cell and the related cytokines IL-17 and TGF-β1 may be involved in the pathogenesis of PA.
Fu S.,Sun Yat Sen University |
Fu S.,Peoples Hospital of ZhongShan |
Xie Y.,Sun Yat Sen University |
Tuo J.,Sun Yat Sen University |
And 5 more authors.
MedChemComm | Year: 2015
This research aims to synthesize lipophilic berberine derivatives and evaluate their antiglioma effects on C6 and U87 cells. The introduction of substituents with various carbon chain lengths on C-13- or C-9-O-position of the berberine scaffold led to the discovery of several potent inhibitors against glioblastoma cells. Derivatives substituted with the carbon chains of moderate length (twelve carbons) displayed improved lipophilicity and the strongest inhibitory effects. Several compounds presented dose-dependent repression against proliferation (IC50, 1.12-6.12 μM) and blocked migration and invasion by over 60% at lower dose levels. Furthermore, preliminary research about the underlying mechanism for the enhanced antiglioma ability indicated that these analogues preferentially localized into mitochondria, inducing the up-regulation of ROS production. Overall, these compounds represent promising candidates to combat glioblastoma and highlight new insight into the antiglioma therapy through interaction with mitochondria. This journal is © The Royal Society of Chemistry 2015.
Liang Z.,Peoples Hospital of Zhongshan |
Quan H.,Peoples Hospital of Zhongshan |
Xu G.,Peoples Hospital of Zhongshan |
Yu A.,Peoples Hospital of Zhongshan
Chinese Journal of Gastroenterology | Year: 2010
Background: Helicobacter pylori (H. pylori) is closely related with chronic gastritis, peptic ulcer, gastric cancer and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, the efficacy of standard triple therapy is decreasing in recent years. Aims: To compare the efficacy of H. pylori eradication with 10-day sequential therapy and standard triple therapy. Methods: A total of 106 patients with peptic ulcer, chronic erosive gastritis and atrophic gastritis who were H. pylori positive proved by rapid urease test (RUT) and 14C-urea breath test (14C-UBT) were randomly divided into two groups. Fifty-six patients were administered with rabeprazole-based 10-day sequential therapy and 50 patients received rabeprazole-based 10-day standard triple therapy. RUT and 14C-UBT were reexamined 4 weeks after a course of treatment to evaluate eradication of H. pylori. The recurrence of H. pylori was assessed by 14C-UBT one-year after eradication treatment of H. pylori. Results: Ninety-three patients completed the study. The H. pylori eradication rates by intention-to-treat (ITT) analysis and by per protocol (PP) analysis in 10-day sequential therapy group were significantly higher than those in 10-day standard triple therapy group (ITT: 89.3% vs. 62.0%, P<0.01; PP: 94.3% vs. 77.5%, P<0.05). The incidence of adverse reactions (7.1% vs. 30.0%, P<0.01) and recurrence rate of H. pylori after one-year follow-up (6.0% vs.25.8%, P<0.01) in 10-day sequential therapy group were significantly lower than those in 10-day standard triple therapy group. Conclusions: In the present study, rabeprazole-based 10-day sequential therapy has achieved a high eradication rate of H. pylori with good patient compliance and less adverse reactions.